NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD)

Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) explained in plain language.

Never miss a new study

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) trials appear

Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New vision injection tested against leading treatment

Disease control Completed

This study tested if a new eye injection called ABP 938 works as well and is as safe as the established drug Eylea for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. About 576 participants with this condition received injections of either the…

Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD)

Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control

Last updated Apr 01, 2026 14:43 UTC

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD)

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (AMD) trials appear

New vision injection tested against leading treatment